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universal and essential function of DOT1L
in multiple cell types may limit its thera-
peutic potential unless a specific thera-
peutic window can be identified to distin-
guish normal versus leukemic cells.
However, the emerging identification of
the epigenetic networks and modifying
enzymes deregulated by MLL fusions will
no doubt continue to provide novel in-
sights and therapeutic avenues to target
these classically nondruggable oncopro-
teins (Figure 1).
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Bone marrow-derived cells have an important role in tumor metastasis and have been reported to ‘‘prime’’
distant tissues for tumor engraftment, although the mechanisms for their recruitment have remained unclear.
A new study by Hiratsuka et al. describes an inflammatory signaling pathway that mediates the chemoattrac-
tion of myeloid and tumor cells to organ-specific metastatic sites.Tumor metastasis is responsible for ap-
proximately 90% of all cancer-related
deaths. It has now been well established
that in order to metastasize from the pri-
mary tumor, cancer cells need to acquire
additional properties that enable invasion
of the extracellular matrix, intravasation,
travel through blood vessels, migration
to and invasion at the secondary site, and
formation of metastatic nodules (Nguyen
and Massague, 2007). Importantly, tumor
cells are not the only participants in this
complex process, as tumor-associated
cells such as macrophages and bone
marrow-derived progenitors have also
been implicated in tumor progression
andmetastasis. There appears tobeacol-
laborative role for these nonmalignant
cells in enhancing metastasis, as they
‘‘precondition’’ the microenvironment inpotential sites of metastasis, promoting
tumor invasion (as reviewed in Wels et al.,
2008).
The elegant early studies by Paget and
Ewing first described the ‘‘seed and soil’’
hypothesis, suggesting that microenvi-
ronmental factors together with mechan-
ical forces of the circulation were both
important determinants of site-specific
metastatic spread. Furthermore, meta-
static progression is considered an
evolutionary process that requires acqui-
sition of additional genetic alterations,
conferring a selective advantage to
unique clones within the tumor cell pop-
ulation and allowing those clones to me-
tastasize (Nguyen and Massague, 2007).
Recently, studies have shown that fac-
tors derived from the primary tumor me-
diate the establishment of specific micro-Cancer Cell 14,environments in distant organs that are
sites of future metastasis, the so-called
‘‘premetastatic niche.’’ But how is it pos-
sible that alterations in the microenviron-
ment of distant organs can occur even
before the first metastatic tumor cell
has arrived? The molecular pathways
that underlie premetastatic niche forma-
tion are the focus of intensive ongoing
study to elucidate the signaling para-
digms that define future secondary tumor
foci.
Over the last several years, a crucial
role for bone marrow-derived cells
(BMDCs) in priming distant tissues for tu-
mor metastasis has been uncovered (Hir-
atsuka et al., 2006; Kaplan et al., 2005). It
has been shown that cells of the hemato-
poietic lineage populate distant organ
tissues prior to the arrival of the tumorNovember 4, 2008 ª2008 Elsevier Inc. 347
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PreviewsFigure 1. The Premetastatic Niche Is Similar to an Inflammatory Nidus
Both S100A8 and S100A9 induce the expression of SAA3 specifically in future metastasis sites in the lung,
promoting Mac1+ myeloid and endothelial cell engraftment. In this process, SAA3 promotes its own
secretion by a positive feedback mechanism mediated by TLR4 and induces NF-kB signaling pathway
activation (left). This inflammation-like state accelerates the future recruitment of tumor cells (right).cells, preparing the premetastatic micro-
environment (Wels et al., 2008). These
BMDCs found in the premetastatic niche
express several progenitor markers such
as VEGFR-1 (Flt-1), c-kit, Sca-1, and
CD11b, characteristic of cells of an im-
mature status. Other molecules such as
fibronectin and MMP9 are also thought
to contribute to creating a highly recep-
tive environment for circulating tumor
cells. In addition to hematopoietic lineage
progenitors, bone marrow-derived endo-
thelial progenitor cells play an essential
role in the formation of the metastatic
niche by enabling the angiogenic switch
associated with the progression of micro-
metastases to macrometastases. Al-
though the molecular basis of this pro-
cess is still unknown, this likely involves348 Cancer Cell 14, November 4, 2008 ª20soluble mediators such as growth factors
and chemokines secreted by cells of the
primary tumor.
To date, little is known about the tumor-
derived secreted factors that mediate the
formation of the premetastatic niche.
Hiratsuka et al. have demonstrated that
primary tumor cells secrete VEGF-A,
TGFb, and TNFa, inducing the expression
of the proinflammatory chemokines
S100A8 (MRP8/calgranulinA) andS100A9
(MRP14/calgranulin B), in the premeta-
static lung microenvironment (Hiratsuka
et al., 2006). These chemoattractants
increase the homing and engraftment of
macrophage antigen 1 (Mac1)-expressing
myeloid cells to premetastatic sites in the
lung, indicating that factors released by
primary tumors induce expression of che-08 Elsevier Inc.mokines within a specific metastatic tar-
get. Many details of this process, such as
why these chemokines are expressed in
specific foci within certain tissues, are still
unclear, and further characterization is
required.
In addition, Hiratsuka et al. found that
engraftment of both Mac1+ myeloid cells
and tumor cells in lung metastatic foci
appeared to be dependent on the p38-
MAPK signaling pathway (Hiratsuka
et al., 2006). In their current study, Hirat-
suka et al. report an extension of these
findings, revealing new signaling path-
ways and molecules involved in this pro-
cess (Hiratsuka et al., 2008). In this work,
serum amyloid A3 (SAA3), a protein previ-
ously implicated in phagocyte chemoat-
traction, is identified as a novel player.
SAA3 is upregulated in specific future tu-
mor metastatic sites by the inflammatory
chemoattractants S100A8 and S100A9
(Hiratsuka et al., 2008). Functional exper-
iments analyzing the role of these proteins
indicated that SAA3 could be a down-
stream molecule for S100A8; however,
the molecular events underlying this
mechanism were not defined. Endothelial
cells and Mac1+ myeloid cells populating
premetastatic sites within the lung appear
to play critical roles in simulating an in-
flammation-like state that promotes mi-
gration of tumor cells to these tissues.
Interestingly, SAA3 protein serves as a
positive feedback regulator for chemoat-
tractant secretion and promotes tumor
cell migration (Figure 1).
The intriguing association between tu-
mor progression and inflammation has
long been a subject of research (Cous-
sens and Werb, 2002). Nuclear factor
kappa B (NF-kB) is a transcription factor
that plays a central role in connecting
inflammation and cancer through stimula-
tion of proinflammatory cytokine pro-
duction in myeloid and lymphoid cells
(Naugler and Karin, 2008). However, the
role of NF-kB signaling in premetastatic
niche formation has not been previously
reported.
In the present study, Hiratsuka et al.
(2008) demonstrate activation of NF-kB
signaling in macrophages in a SAA3-de-
pendent fashion. This finding raises the
intriguing possibility that NF-kB in the pre-
metastatic niche could be functioning to
prepare a metastatic-like environment
for primary tumor cells (Figure 1). Remark-
ably, Toll-like receptor 4 (TLR4) seems to
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Previewsbe the critical receptor for SAA3 during
the inflammatory-like response in the pre-
metastatic niche. Moreover, while primary
tumor cell growth was not impaired by the
absence of TLR4, deletion of this receptor
both dramatically decreased the number
of metastatic tumor sites and reduced
the engraftment of Mac1+ myeloid cells
in those sites. Additionally, Mac1+ cell re-
cruitment to future metastatic sites was
impaired in TLR4/ mice, suggesting
that Toll-like receptor signaling may play
a critical role in the crosstalk between tu-
mor cells and BMDCs during premeta-
static niche formation. Finally, inhibition
of SAA3 function by neutralizing anti-
bodies abolished cell migration to preme-
tastatic lung sites by blocking the recruit-
ment of both BMDCs and tumor cells,
indicating that interfering with SAA3-
TLR4 signaling may have a therapeutic
benefit in delaying or preventing tumor
metastasis.
Taken together, these data shed new
light on the molecular mechanisms of
premetastatic niche formation and sug-
gest that this process is analogous to an
inflammatory nidus. However, many
questions still remain. For example, why
does SAA3-TLR4 signaling promote the
expression of inflammatory chemoattrac-Regulating the Co
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melanoma cell metastasis.
Two properties that differentiate malig-
nant cancer from benign are local tissue
invasion by tumor cells and metastasis
to sites separate from the primary tumor.
In fact, metastasis is the main factor ac-
counting for cancer treatment failure andtants in some specific tissue types (such
as lung) but not others? Furthermore,
there may also be as yet unrecognized in-
teractions between these cells and other
inflammatory cells such as lymphocytes
and fibroblasts, and also changes in the
extracellular matrix. It is unclear what
role other Toll-like receptors may play in
the premetastatic phase, not only on im-
mune cells but also on tumor cells, where
they may influence tumor growth and
host immune responses (Huang et al.,
2008). It is also unclear from this study
whether the proinflammatory cytokine
TNFa can act independently from the
SAA3-TLR4 and NF-kB pathways as
shown recently by Oguma et al. (2008).
These differences may emphasize the
variations in the molecular events occur-
ring during development of the primary
tumor and during the establishment of
metastatic disease.
Although there aremanymore details to
be unraveled, Hiratsuka et al. have made
great strides toward describing the earli-
est stages in metastasis formation, un-
covering important roles for inflammatory
signaling pathways such as p38 and NF-
kB in premetastatic niche formation and
in recruitment of both supportive BMDCs
and disseminating cancer cells. These ad-nversion between
des of Cancer Cell
arscube Estate, Switchback Road, Bearsden, G
k
ounded modes of movement allows in
issue of Cell, Sanz-Moreno et al. ide
ting Rac and Rho signaling that determ
is responsible for 90% of cancer deaths
(Hanahan and Weinberg, 2000). Due to
the significant impact that invasion and
metastasis have on cancer mortality, in-
tense research effort is directed at deter-
mining the critical molecular components
Cancer Cell 14,ditional clues could be used to develop
new and much-needed therapeutic strat-
egies to prevent organ-specific meta-
static spread.
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vasive tumor cells to adapt to vary-
ntify DOCK3, NEDD9, WAVE2, and
ine the mode of movement driving
involved, in the hope that this knowledge
will eventually improve diagnosis and
treatment (Olson and Sahai, 2008).
In vivo, tumor cells must break away
from the primary cell mass, move through
tissues by deforming and/or degrading
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